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We read with interest the safety review paper by Moore et al. (1)
aimed at outlining the available information on the safety of atrial
septal defect (ASD) closure devices (Amplatzer septal occluder
[ASO], St. Jude Medical, St. Paul, Minnesota, and Helex septal
occluder, W.L. Gore, Flagstaff, Arizona) with a focus on cardiac
perforation.
In this endeavor, the authors of that paper quoted the analysis
by DiBardino et al. (2), which presented 51 cardiac perforations
reported to the Manufacturer and MAUDE (User Facility Device
Experience) database, with a concerning overall mortality of 19.6%
and evidence that ruptures may occur as late as 3 years after
deployment.
Similarly, Moore et al. (1) reported a MAUDE database
analysis by the U.S. Food and Drug Administration showing how
erosion contributes to 15% of medical device reports, with an
overall 16.2% mortality in 80 patients who required device removal.
Again, the time to erosion reported in the 13 deaths ranged from
1 day to 2.2 years (3).
Cardiac perforation is a rare complication of ASD closure de-
vices, not encountered in the pivotal or post-market approval
studies, which is particularly troubling in view of the potential for
late occurrence, the few convincing data on risk factors, and the
impending catastrophic outcome.
Although not quoted by Moore et al. (1), we reported the
longest time frame (5 years) ever recorded for an ASO-related
cardiac perforation, which occurred during an intense isometric
exertion in a 54-year-old patient (4).
Although anecdotal, our observation might have 2-fold impor-
tance. On the one hand, the potential for an even more delayed
adverse event should not be underestimated. Indeed, this late
occurrence might suggest a more cautious revision of the follow-up
imaging schedule after device implantation (1).
On the other hand, the occurrence of the event during an intense
isometric exertion raises the question whether dynamic changes in
the anatomic relationship between the device and surrounding
cardiac structures, particularly during Valsalva maneuvers or other
pressurizing conditions, might play a role in the determinism of the
complication. This issue could be of the utmost importance in
people exposed to strenuous physical activity.
This hypothesis might suggest 2 precautionary initiatives: 1) the
introduction of stress echocardiography in the routine assessment
of patients after ASD closure device implantation to evaluate the
appropriateness of the device positioning under dynamic condi-
tions; and 2) greater restriction imposed during intense physical
activity in ASD closure devices holders until this issue is ﬁnally
elucidated.*Francesco Santini, MD
Francesco Onorati, MD
Filippo Rapetto, MD
Giancarlo Passerone, MD
Giuseppe Faggian, MD
Alessandro Mazzucco, MD
*Division of Cardiac Surgery
IRCCS Azienda Ospedaliera Universitaria San Martino – IST
Largo Rosanna Benzi 10
16132 Genova
Italy
E-mail: francesco.santini@univr.it
http://dx.doi.org/10.1016/j.jcin.2013.07.016REFERENCES
1. Moore J, Hegde S, El-Said H, et al. Transcatheter device closure of
atrial septal defects. J Am Coll Cardiol Intv 2013;5:433–42.
2. DiBardino DJ, McElhinney DB, Kaza AK, Mayer JE. Analysis of the
U.S. FDA Manufacturer and User Facility Device Experience database
for adverse events involving Amplatzer septal occluder devices and
comparison with the STS congenital cardiac surgery database. J Thorac
Cardiovasc Surg 2009;137:1334–41.
3. U.S. FDA. FDA Executive Summary Memorandum—May 24, 2012:
Circulatory System Advisory Panel Meeting—Transcatheter ASD
Occluders: Clinical Update and Review of Events [pdf]. May 24, 2012.
Available at: http://www.fda.gov/AdvisoryCommittees/CommitteesMeeting
Materials/MedicalDevices/MedicalDevicesAdvisoryCommittee/Circulatory
System DevicesPanel/ucm300073.htm. Accessed December 4, 2012
4. Santini F, Morjan M, Onorati F, Morando G, Faggian G, Mazzucco A.
Life-threatening isometric-exertion related cardiac perforation 5 years
after Amplatzer septal defect closure: should isometric activity be limited
in septal occluder holders? Ann Thorac Surg 2012;93:671.
Reply
Cardiac Perforation by Atrial Septal Defect
Closure Devices: A Potentially Catastrophic
and Still Unclear Event
We thank Dr. Santini and colleagues for their interest in our paper
(1). Santini and colleagues discuss a hypothetical cause of erosion
based on an anecdotal report stemming from 1 patient who had a
device-related cardiac perforation following a period of intense
isometric exercise. We did not reference the report by Santini et al.
(2), but we acknowledge that a period of intense exercise could
potentially bring about hemodynamic changes that may alter the
relationship between the device and surrounding structures and,
thereby, increase the risk for erosion. However, this hypothesis is
based on a single case report. As alluded to in our review, erosions
are rare, with the overall incidence of erosions ranging from 0.1%
to 0.3% and with mortality from erosion being around 0.05%,
